



The Pharmacogenomics of Mood Stabilizers

Guest Editors:

Dr. Alessio Squassina

Laboratory of
Pharmacogenomics, Division of
Neuroscience and Clinical
Pharmacology, Department of
Biomedical Sciences, University
of Cagliari, Cagliari, Italy

Dr. Gabriel R. Fries

Translational Psychiatry
Program, Louis A. Faillace, MD,
Department of Psychiatry and
Behavioral Sciences, Center for
Precision Health, School of
Biomedical Informatics, Houston,
TX, USA

Deadline for manuscript
submissions:

closed (30 September 2021)

Message from the Guest Editors

Dear Colleagues,

The field of pharmacogenomics has experienced unprecedented progress in the last decade. Nevertheless, the translational value of pharmacogenomics of psychotropic medications is still hampered by our limited knowledge on their mechanisms of action and by the phenotypic and biological complexity of psychiatric disorders. The genomic era has made it possible to identify several genes which might significantly contribute to the etiopathogenesis of mood disorders, while pharmacogenomic and pharmacotranscriptomic studies brought us closer to a deeper comprehension of the clinically relevant targets of mood stabilizers—especially in the case of lithium.

For this Special Issue we invite you to contribute original articles or review articles on the different aspects of the pharmacogenomics of mood stabilizers, including studies exploring or reviewing the role of biological systems, either in patients, human-derived cell lines, or animal models, as well as studies implementing statistical approaches to better exploit the large amount of genetic data produced by the pharmacogenomic studies in this field.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com